Literature DB >> 23990267

Moving toward a better understanding of radioiodine action.

Alan L Ho1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23990267     DOI： 10.1007/s12020-013-0024-x

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  8 in total

1.  Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

Authors:  C Durante; N Haddy; E Baudin; S Leboulleux; D Hartl; J P Travagli; B Caillou; M Ricard; J D Lumbroso; F De Vathaire; M Schlumberger
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

2.  Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.

Authors:  Debyani Chakravarty; Elmer Santos; Mabel Ryder; Jeffrey A Knauf; Xiao-Hui Liao; Brian L West; Gideon Bollag; Richard Kolesnick; Tin Htwe Thin; Neal Rosen; Pat Zanzonico; Steven M Larson; Samuel Refetoff; Ronald Ghossein; James A Fagin
Journal:  J Clin Invest       Date:  2011-11-21       Impact factor: 14.808

3.  Radioiodide induces apoptosis in human thyroid tissue in culture.

Authors:  Eleonora Russo; Anna Guerra; Vincenzo Marotta; Antongiulio Faggiano; Annamaria Colao; Silvana Del Vecchio; Massimo Tonacchera; Mario Vitale
Journal:  Endocrine       Date:  2013-03-31       Impact factor: 3.633

4.  Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study.

Authors:  D Simon; C Körber; M Krausch; J Segering; P Groth; R Görges; F Grünwald; H W Müller-Gärtner; C Schmutzler; J Köhrle; H D Röher; C Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-13       Impact factor: 9.236

5.  Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma.

Authors:  Jennifer A Woyach; Richard T Kloos; Matthew D Ringel; Daria Arbogast; Minden Collamore; James A Zwiebel; Michael Grever; Miguel Villalona-Calero; Manisha H Shah
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

6.  Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

Authors:  Alan L Ho; Ravinder K Grewal; Rebecca Leboeuf; Eric J Sherman; David G Pfister; Desiree Deandreis; Keith S Pentlow; Pat B Zanzonico; Sofia Haque; Somali Gavane; Ronald A Ghossein; Julio C Ricarte-Filho; José M Domínguez; Ronglai Shen; R Michael Tuttle; Steve M Larson; James A Fagin
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

7.  Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma.

Authors:  Eric J Sherman; Yungpo Bernard Su; Ashima Lyall; Heiko Schöder; Matthew G Fury; Ronald A Ghossein; Sofia Haque; Donna Lisa; Ashok R Shaha; R Michael Tuttle; David G Pfister
Journal:  Thyroid       Date:  2013-05       Impact factor: 6.568

8.  13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study.

Authors:  Daria Handkiewicz-Junak; Jozef Roskosz; Kornelia Hasse-Lazar; Sylwia Szpak-Ulczok; Zbigniew Puch; Aleksandra Kukulska; Tomasz Olczyk; Andrzej Piela; Ewa Paliczka-Cieslik; Barbara Jarzab
Journal:  Thyroid Res       Date:  2009-08-01
  8 in total
  1 in total

1.  Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.

Authors:  Vincenzo Marotta; Carolina Di Somma; Manila Rubino; Concetta Sciammarella; Roberta Modica; Luigi Camera; Michela Del Prete; Francesca Marciello; Valeria Ramundo; Luisa Circelli; Pasqualina Buonomano; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2014-10-11       Impact factor: 3.633
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.